Major shareholder Bioventures 2014 L.P. Mpm has divested 59,277 shares of Werewolf Therapeutics, Inc. (NASDAQ: HOWL) in a transaction completed on December 2, 2023. The shares were sold at an average price of $0.89, resulting in a total transaction value of $52,756.53. Following this sale, Bioventures holds 4,924,566 shares of the company, valued at approximately $4,382,863.74, marking a 1.19% reduction in their ownership stake.
The transaction was publicly disclosed through a filing with the Securities and Exchange Commission (SEC), which outlines the required reporting for large shareholders owning at least 10% of a company’s stock.
Current Market Performance
On the day following the sale, Werewolf Therapeutics’ stock opened at $0.95. The stock’s performance shows a fifty-day moving average of $1.37 and a two-hundred day moving average of $1.33. Over the past year, shares have fluctuated between a low of $0.60 and a high of $2.38. The company currently has a market capitalization of $46.20 million, a price-to-earnings ratio of -0.59, and a debt-to-equity ratio of 0.73.
Analyst Ratings and Institutional Activity
Recent analyses have influenced investor sentiment regarding Werewolf Therapeutics. Zacks Research downgraded the stock from a “strong-buy” to a “hold” rating on November 21. Meanwhile, Citigroup maintained a “market outperform” rating as of November 12. JMP Securities has adjusted its target price for the stock from $4.00 to $3.00, while Bank of America reduced its target from $8.00 to $7.00 on November 18.
Five analysts have rated Werewolf Therapeutics with a “Buy,” one has given it a “Hold,” and one has issued a “Sell” rating. According to MarketBeat.com, the consensus rating is “Moderate Buy” with a target price of $7.75.
Institutional investors have also been active, with Charles Schwab Investment Management Inc. increasing its holdings by 33.2% in the first quarter, now owning 95,712 shares valued at $93,000. MPM Asset Management LLC raised its stake by 0.6%, owning 4,309,860 shares after acquiring an additional 25,688 shares. Other notable transactions include Nuveen LLC acquiring a new stake valued at $71,000 and MPM Bioimpact LLC increasing its holdings by 0.9%.
Company Overview
Werewolf Therapeutics, Inc. is a biopharmaceutical firm focused on developing therapies designed to enhance the body’s immune response for cancer treatment. The company utilizes its proprietary PREDATOR platform to create conditionally activated molecules aimed at improving both adaptive and innate immunity, addressing the shortcomings of traditional proinflammatory immune therapies.
Investors and analysts will continue to monitor the stock as further developments unfold in the coming weeks.
